Thrombosis
Disease2 papers5 findings
A human study associates metformin with lower thrombosis risk in polycythaemia vera or essential thrombocythaemia with diabetes, but not mild diabetes. One mouse study reports reduced thrombosis with indole-3-propionic acid, and with intermittent fasting in obese mice.
- Humans1
- Animals1
Interventions
2Metformin
no changein humans1HR 0.87Low certainty
1 study
Metformin
no changein humans1HR 0.87Low certainty
Metformin has no effect on thrombosis in humans (HR 0.87, 95% CI 0.68–1.11; no significant association).
HumansPolycythemia vera or essential thrombocythemia and mild diabetesn = 846
Metformin linked to fewer clots in blood cancer and diabetes · Blood advances · 6 Oct 2026
INDOLE-3-PROPIONIC acid
downin mice1Very low certainty
1 study
INDOLE-3-PROPIONIC acid
downin mice1Very low certainty
INDOLE-3-PROPIONIC acid decreases thrombosis in mice.
Animalsin vivo
Alternate day fasting attenuates metabolic dysfunction-associated arterial thrombotic risk via increasing indole-3-propionic acid · Cell reports · 23 Sep 2026
Associations
3Metformin
downin humans1HR 0.78Low certainty
1 study
Metformin
downin humans1HR 0.78Low certainty
Metformin is associated with thrombosis in humans (HR 0.78, 95% CI 0.64–0.95).
HumansPolycythemia vera or essential thrombocythemia and diabetes≥6 months after diagnosisn = 1,153
Metformin linked to fewer clots in blood cancer and diabetes · Blood advances · 6 Oct 2026
INDOLE-3-PROPIONIC acid
downin humans1
1 study
INDOLE-3-PROPIONIC acid
downin humans1
Thrombosis is associated with INDOLE-3-PROPIONIC acid in humans.
Humanspatients with metabolic disturbance-associated arterial thrombosis
Alternate day fasting attenuates metabolic dysfunction-associated arterial thrombotic risk via increasing indole-3-propionic acid · Cell reports · 23 Sep 2026
Intermittent fasting
downin mice1Very low certainty
1 study
Intermittent fasting
downin mice1Very low certainty
Intermittent fasting lowers the risk of thrombosis in mice.
Animalsin obese mice
Alternate day fasting attenuates metabolic dysfunction-associated arterial thrombotic risk via increasing indole-3-propionic acid · Cell reports · 23 Sep 2026
Trial sponsors
Company1 trialPhase 33,202 people
Company1 trialPhase 31,000 people
Company1 trialPhase 3231 people
Johnson and Johnson Pharmaceutical Research and Development
Company1 trialPhase 3112 people
Company5 trialsPhase 21,089 people
Hallym University Medical Center
2 trialsPhase 4360 people
1 trialPhase 41,000 people
1 trialPhase 4447 people
Latest
7Metformin linked to fewer clots in blood cancer and diabetes
Metformin users had lower blood clot risk than non-users, with a hazard ratio of 0.78, a measure comparing risk over time.Metformin users had lower blood clot risk than non-users, with a hazard ratio of 0.78, a measure comparing risk over time.